Overview

Phase III Copanlisib in Rituximab-refractory iNHL

Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
To assess the safety of copanlisib.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Pharmaceutical Solutions
Rituximab